Brief Summary:
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of
luspatercept, to the following participants:
- Participants receiving luspatercept on a parent protocol at the time of their transition
to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial
and, in the opinion of the investigator, may derive clinical benefit from continuing
treatment with luspatercept
- Participants in the follow-up phase previously treated with luspatercept or placebo in
the parent protocol will continue into long-term post-treatment follow-up in the
rollover study until the follow-up commitments are met
- The study design is divided into the Transition Phase, Treatment Phase and Follow-up
Phase. Participants will enter transition phase and depending on their background will
enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU)
phase
- Transition Phase is defined as one Enrollment visit
- Treatment Phase: For participants in luspatercept treatment the dose and schedule of
luspatercept in this study will be the same as the last dose and schedule in the parent
luspatercept study. This does not apply to participants that are in long-term follow-up
from the parent protocol
- Follow-up Phase includes:
- 42 Day Safety Follow-up Visit
- During the Safety Follow up, the participants will be followed for 42 days after the
last dose of luspatercept, for the assessment of safety-related parameters and adverse
event (AE) reporting
- Long-term Post-treatment Follow-up (LTPTFU) Phase
- Participants will be followed for overall survival every 6 months for at least 5 years
from first dose of luspatercept in the parent protocol, or 3 years of post-treatment
from last dose, whichever occurs later, or until death, withdrawal of consent, study
termination, or until a subject is lost to follow-up. Participants will also be
monitored for progression to AML or any malignancies/pre-malignancies. New anticancer or
disease related therapies should be collected at the same time schedule
Participants transitioning from a parent luspatercept study in post-treatment follow-up
(safety or LTPTFU) will continue from the same equivalent point in this rollover study.
The rollover study will be terminated, and relevant participants will discontinue from the
study when all participants fulfill at least 5 years from the first dose of luspatercept in
the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later.
Inclusion Criteria:
Participants must meet all the following criteria to be enrolled in this study:
1. Participant is ≥ 18 years at the time of signing the informed consent form (ICF).
2. Participant is willing and able to adhere to the study visit schedule and other
protocol requirements.
3. Participant has been participating in a luspatercept trial and continues to fulfill
all the requirements of the parent protocol and the participant has been either:
1. Assigned to luspatercept treatment, continues to receive clinical benefit in the
opinion of the investigator and should continue to receive luspatercept
treatment, OR
2. Assigned to placebo arm in the parent protocol (at the time of unblinding or in
follow-up) and should cross over to luspatercept treatment, OR
3. Assigned to the Follow-up Phase of the parent protocol, previously treated with
luspatercept or placebo in the parent protocol who shall continue into Long-term
Post-treatment Follow-up Phase in the rollover study until the follow-up
commitments are met (unless requirements are met as per parent protocol to
crossover to luspatercept treatment).
4. Participant understands and voluntarily signs an informed consent document prior to
any study-related assessments or procedures being conducted.
5. Participant demonstrates compliance, as assessed by the investigator, with the parent
study protocol requirements.
6. Applies to on treatment Participants only- females of childbearing potential (FCBP)
defined as a sexually mature woman who:
1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral
oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer
therapy or amenorrhea due to other medical reasons does not rule out childbearing
potential) for at least 24 consecutive months (ie, has had menses at any time in the
preceding 24 consecutive months) and must:
1. Have two negative pregnancy tests as verified by the investigator prior to starting
study therapy. She must agree to ongoing pregnancy testing during the course of the
study, and after end of study therapy. This applies even if the participant practices
true abstinence* from heterosexual contact.
2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on
a monthly basis and source documented) or agree to use, and be able to comply with
highly effective, contraception without interruption, 35 days prior to starting
investigational product (IP), during the study therapy (including dose interruptions),
and for 84 days after discontinuation of study therapy.
7. Applies to on treatment participants only- Male participants must:
a. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a
condom during sexual contact with a pregnant female or a female of childbearing potential
while participating in the study, during dose interruptions and for at least 84 days
following investigational product discontinuation even if he has undergone a successful
vasectomy.
Exclusion Criteria:
The presence of any of the following will exclude a participant from enrollment:
1. Applies to on treatment participants only- Concomitant use of any
medications/procedures that are prohibited in the parent luspatercept protocol.
2. Participant has met one or more criteria for study discontinuation as stipulated in
the parent luspatercept protocol.
3. Applies to on treatment participants only- More than 26 days between last luspatercept
dose in the parent protocol and first dose into ACE-536-LTFU-001 protocol unless dose
delay or dose discontinuation criteria met.
4. Applies to on treatment participants only- Pregnant or breastfeeding females.
5. Participant has any significant medical condition, laboratory abnormality, psychiatric
illness, or is considered vulnerable by local regulations (eg, imprisoned or
institutionalized) that would prevent the subject from participating in the study.
6. Participant has any condition including the presence of laboratory abnormalities,
which places the subject at unacceptable risk if he/she were to participate in the
study.
7. Participant has any condition that confounds the ability to interpret data from the
study.
Primary outcome:
1. Adverse Events (AEs) (Time Frame - From enrollment until at least 42 Day Safety Follow-up Phase or EOS (Approximately 5 years).):
Type, frequency, severity of AEs, relationship of treatment emergent adverse events to luspatercept
2. Number of participants progressing to high/very high risk MDS or AML. (Time Frame - Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)):
Progression to high/very high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (MDS and myelofibrosis [MF] only).
3. Percentage of participants progressing to high/very high risk MDS or AML (Time Frame - Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)):
Progression to high/very high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (MDS and myelofibrosis [MF] only)
4. Number of participants developing other malignancies/pre-malignancies (Time Frame - Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)):
Development of other malignancies/pre-malignancies
5. Percentage of participants developing other malignancies/pre-malignancies (Time Frame - Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)):
Development of other malignancies/pre-malignancies
Secondary outcome:
1. Overall Survival (Time Frame - Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)):
Time from date of randomization until death from any cause
2. Number of participants developing treatment emergent extramedullary hematopoiesis (EMH) masses (Time Frame - Enrollment to Long-term post-treatment follow-up (Approximately, 5 years))
3. Percentage of participants developing treatment emergent EMH masses (Time Frame - Enrollment to Long-term post-treatment follow-up (Approximately, 5 years))
- Luspatercept (ACE-536):
Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
Quelle: ClinicalTrials.gov
